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Dear Editor,
A 58-year-old man presented with bilateral, persistent steroid
refractory vitritis in 2005. Repeated vitreous biopsies in 2006
and 2007 were inconclusive. In late 2008, he developed
vertigo and amagnetic resonance imaging (MRI) scan showed
an intra-axial infratentorial tumor with marked cerebellar ede-
ma. Brain biopsy showed diffuse large B cell lymphoma
(DLCL). Systemic staging, including lumbar puncture, was
negative. He was treated as combined intraocular lymphoma
(IOL) and primary brain lymphoma (PBL) with chemotherapy
[four courses high-dose methotrexate (MTX), rituximab, vin-
cristine, and procarbazine] followed by whole brain radiother-
apy (RT, 40 Gy) [1]. This resulted in clinical and radiological
remission. Further treatment was limited by poor performance
status and renal impairment.
His vision remained impaired due to bilateral grade 3 poste-
rior subcapsular cataract and grade 2 cortical cataract. Right eye
phaco-emulsification with implantation of posterior chamber
intraocular lens was performed in 2008 with good visual recov-
ery. However, his left eye showed progressively decreased acuity
to hand movement. An examination showed keratic precipitates,
dense cataract, vitritis, retinal infiltrates, and hemorrhages. An
MRI and lumbar puncture remained normal. He was treated as
recurrent IOL with intrathecal (IT) MTX and cytosine arabino-
side (Ara-C). Subsequent left eye cataract surgery and vitreous
biopsy showed small lymphocytes but no malignant cells, but
panuveitis persisted despite further anterior sub-Tenon’s triam-
cinolone acetonide injection. A repeat pars plana vitrectomywas
performed in 2009. The histology showed large sized atypical
lymphoid cells, but an immunogloubin heavy chain polymerase
chain reaction study showed no clonality. In view of likely
persistent IOL, additional dose-limiting conformal RTwas given
to both eyes (1.8 Gy/fr up to 28.2 Gy). Vision in his right eye
remained good (0.5), but his left eye deteriorated to no light
perception. By 2011, he developed left eye pain, florid vitritis,
hypopyon, and glaucoma (40mmHg, Fig. 1a). The painful blind
eye was enucleated (Fig. 1b). The specimen showed abundant
CD20 positive lymphoma cells in both chambers of the eye
(Fig. 1c, d) with frequent mitotic figures and necrosis. Six
months later, radiological and physical examinations showed
no evidence of brain or orbital lymphoma (Fig. 1e).
The related pathologies of IOL and PBL may occur con-
currently or sequentially. Central nervous system (CNS)
investigation and therapy are advised for apparent isolated
IOL [2, 3]. Meticulous fundal examination is also mandatory
for PBL patients [4]. The incidence, time sequence, and inter-
val between the entities vary and may be related to the ana-
tomical location of the PBL lesion [5]. Histologically, both
conditions are related and extra-CNS spread is uncommon [4].
The treatment includes high dose systemic and IT MTX, Ara-
C, and RT [1, 3, 6]. The long-term visual, neurological, and
survival prognosis is usually guarded [4, 6].
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Our patient is unique in a number of ways. Although IOL
is a well-known ophthalmological masquerade lesion, a 3-
year lapse between IOL and PBL without treatment is un-
usual. In addition, the IOL was exquisitely localized to the
globe, evident by its isolated nonresponse to chemotherapy,
first in both eyes and eventually only in the left eye [6].
After failing multiple maximal dose therapies, the options
for a frail patient become limited [1]. The hypopyon is
indicative of fulminant lymphoma in the aqueous chamber
[2]. Intraocular chemotherapy injection is invasive and may
breach the capsular sealing of the amorphous DLCL. It is
unlikely to be effective against refractory DLCL. The role of
temozolamide or intraocular rituximab is uncertain [7]. His-
torically, the first effective treatment of IOL was enucleation
(c.f. ocular melanoma and retinoblastoma) [6]. Although
relegated to a historical curiosity, IOL enucleation remerged
as a novel option in our very unique case with refractory
localized cells in a painful blind eye. Disease and symptom
control was achieved with minimal morbidity.
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Fig. 1 a Left eye hypopyon
(arrow) of sedimentation of
lymphoma cells. b Gross
specimen bisected globe with
extensive amorphous white
infiltrations representing the
hypopyon. c Photomicrograph
of anterior chamber with
abundant lymphoma cell
infiltration (arrows) between
the cornea (asterisk) and iris
(×40 magnification). d
Photomicrograph of posterior
chamber with profuse
lymphoma cell infiltration
(arrows) in front of the capsule
of globe (asterisk) and the
choroid–retina layer (×40
magnification). e Follow-up
MRI scan showing replacement
glass eye (arrow) with no
evidence of parenchymal or
global disease
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